Express Pharma

DECEMBER 2, 2024

The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.

Labelling 126

Labelling Diabetes Drug Development 126

Pharmaceutical Technology

JUNE 7, 2023

The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

Quality Matters

SEPTEMBER 9, 2024

The area is populated with apps and other software designed to treat various ailments including mental health disorders, diabetes, asthma, insomnia, substance-use disorders, and beyond. In the meantime, USP encourages interested parties to apply to become involved in developing DTx standards as a USP Expert Volunteer in the 2025-2030 cycle.

Labelling 52

Labelling Diabetes 52

PharmaShots

MAY 3, 2023

Eli Lilly Launches Rezvoglar as Second Interchangeable Insulin Biosimilar in the US Date- April 01, 2023 Product: Rezvoglar The company launched Rezvoglar, a second interchangeable biosimilar insulin product to Lantus (insulin glargine) in the US market for the treatment of patients with diabetes. Infections were observed in 33.9%

Biosimilars 56

Biosimilars Labelling Diabetes 56